Metformin may lower colorectal cancer risk by stopping precancerous lesion formation
the ONA take:
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.
Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.
Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.
Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.
“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|